PMC:7361557 / 1017-1284 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"38","span":{"begin":19,"end":27},"obj":"Species"},{"id":"46","span":{"begin":10,"end":18},"obj":"Disease"},{"id":"47","span":{"begin":182,"end":195},"obj":"Disease"}],"attributes":[{"id":"A38","pred":"tao:has_database_id","subj":"38","obj":"Tax:9606"},{"id":"A46","pred":"tao:has_database_id","subj":"46","obj":"MESH:C000657245"},{"id":"A47","pred":"tao:has_database_id","subj":"47","obj":"MESH:D006943"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"In severe COVID‐19 patients with T2DM, we demonstrate a higher risk of all‐cause fatality with glucocorticoid treatment (Adjusted HR, 3.61; 95%CI, 1.14‐11.46; P = 0.029), and severe hyperglycemia (FPG ≥11.1 mmol/L) (Adjusted HR, 11.86; 95%CI, 1.21‐116.44; P = 0.034)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T15","span":{"begin":10,"end":18},"obj":"Disease"},{"id":"T16","span":{"begin":182,"end":195},"obj":"Disease"}],"attributes":[{"id":"A15","pred":"mondo_id","subj":"T15","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A16","pred":"mondo_id","subj":"T16","obj":"http://purl.obolibrary.org/obo/MONDO_0002909"}],"text":"In severe COVID‐19 patients with T2DM, we demonstrate a higher risk of all‐cause fatality with glucocorticoid treatment (Adjusted HR, 3.61; 95%CI, 1.14‐11.46; P = 0.029), and severe hyperglycemia (FPG ≥11.1 mmol/L) (Adjusted HR, 11.86; 95%CI, 1.21‐116.44; P = 0.034)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T9","span":{"begin":54,"end":55},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"In severe COVID‐19 patients with T2DM, we demonstrate a higher risk of all‐cause fatality with glucocorticoid treatment (Adjusted HR, 3.61; 95%CI, 1.14‐11.46; P = 0.029), and severe hyperglycemia (FPG ≥11.1 mmol/L) (Adjusted HR, 11.86; 95%CI, 1.21‐116.44; P = 0.034)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T2","span":{"begin":182,"end":195},"obj":"Phenotype"}],"attributes":[{"id":"A2","pred":"hp_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/HP_0003074"}],"text":"In severe COVID‐19 patients with T2DM, we demonstrate a higher risk of all‐cause fatality with glucocorticoid treatment (Adjusted HR, 3.61; 95%CI, 1.14‐11.46; P = 0.029), and severe hyperglycemia (FPG ≥11.1 mmol/L) (Adjusted HR, 11.86; 95%CI, 1.21‐116.44; P = 0.034)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T14","span":{"begin":0,"end":267},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In severe COVID‐19 patients with T2DM, we demonstrate a higher risk of all‐cause fatality with glucocorticoid treatment (Adjusted HR, 3.61; 95%CI, 1.14‐11.46; P = 0.029), and severe hyperglycemia (FPG ≥11.1 mmol/L) (Adjusted HR, 11.86; 95%CI, 1.21‐116.44; P = 0.034)."}